AKBM Stock Overview
Engages in harvesting krill and supplies krill-derived products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for AKBM from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Partnerships In Japan And China Will Expand Kori Brand's International Reach
My Notes
Capture your thoughts, links and company narrative
Aker BioMarine AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 66.70 |
| 52 Week High | NOK 109.80 |
| 52 Week Low | NOK 42.30 |
| Beta | 0.76 |
| 1 Month Change | 0.76% |
| 3 Month Change | 16.81% |
| 1 Year Change | 25.85% |
| 3 Year Change | 44.06% |
| 5 Year Change | n/a |
| Change since IPO | -36.29% |
Recent News & Updates
Is Aker BioMarine (OB:AKBM) Using Too Much Debt?
Feb 15
Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Dec 20Recent updates
Is Aker BioMarine (OB:AKBM) Using Too Much Debt?
Feb 15Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Dec 20Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 08Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors
Nov 05At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?
Aug 20Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking
Jul 19What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates
Jul 16There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
Jul 11These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way
Jun 03There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues
Feb 15There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
Nov 06Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)
Sep 06We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings
Nov 04Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability
Apr 13Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 18Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven
Jan 07Shareholder Returns
| AKBM | NO Food | NO Market | |
|---|---|---|---|
| 7D | -6.1% | -2.9% | 0.5% |
| 1Y | 25.8% | 9.3% | 9.0% |
Return vs Industry: AKBM exceeded the Norwegian Food industry which returned 9.3% over the past year.
Return vs Market: AKBM exceeded the Norwegian Market which returned 9% over the past year.
Price Volatility
| AKBM volatility | |
|---|---|
| AKBM Average Weekly Movement | 5.9% |
| Food Industry Average Movement | 4.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 12.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: AKBM has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: AKBM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 373 | Matts Johansen | www.akerbiomarine.com |
Aker BioMarine AS engages in harvesting krill and supplies krill-derived products worldwide. It operates through two segments, Ingredients and Brands. The Ingredients segment is involved in the offshore harvesting and production, logistical operations, and onshore manufacturing and sales of krill-derived products for nutraceutical, pet food, and aquaculture industries.
Aker BioMarine AS Fundamentals Summary
| AKBM fundamental statistics | |
|---|---|
| Market cap | NOK 5.85b |
| Earnings (TTM) | -NOK 159.01m |
| Revenue (TTM) | NOK 2.21b |
2.6x
P/S Ratio-36.8x
P/E RatioIs AKBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBM income statement (TTM) | |
|---|---|
| Revenue | US$198.90m |
| Cost of Revenue | US$129.90m |
| Gross Profit | US$69.00m |
| Other Expenses | US$83.30m |
| Earnings | -US$14.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Mar 31, 2025
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 34.69% |
| Net Profit Margin | -7.19% |
| Debt/Equity Ratio | 84.8% |
How did AKBM perform over the long term?
See historical performance and comparisonDividends
67.5%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 01:03 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aker BioMarine AS is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Ola Trovatn | DNB Markets |
| Carl-Emil Johannessen | Pareto Securities |